Alzheimer disease

Alois Alzheimer

At the 37th Meeting of Southwest German Psychiatrists held in Tübingen in November 1906, Alzheimer presented the clinical and neuropathological findings on a woman aged 51 years suffering from an ‚unusual disease of the cerebral cortex' (Eine eigenartige Erkrankung der Hirnrinde) which caused memory loss, disorientation followed by depression and hallucinations. Pathological examination revealed atrophy and specific lesions which he described as a "paucity of cells in the cerebral cortex and clumps of filaments between the nerve cells". Alzheimer's report on his patient Augusta D. was published in the following year. It was not a full size paper but rather a short abstract summarizing his presentation at the meeting (Alzheimer, 1907, Alzheimer et al, 1995). The paper did not contain any illustrations, first drawings of plaques and tangles were published by Alzheimer later in his comprehensive article on the histopathology of Alzheimer's disease (Alzheimer, 1911), where he provided a review of the histopathological spectrum of Alzheimer's disease ranging from "plaque only" to "tangles and plaques" forms (Graeber et al, 1997, 1998).

Alzheimer's findings were followed up, and soon a number of reports of similar cases had appeared in the literature. Solomon Fuller summarized clinical and pathological reports from 12 other cases that had been published within 5 years (Bick, 1994). In 1910 Emil Kraepelin in his influential Textbook of Psychiatry (Psychiatrie: Ein Lehrbuch für Studierende and Aerzte) proposed naming the disease condition after Alzheimer (Holstein, 1997, Berchtold and Cotman, 1998). In the Textbook he stated: "The clinical interpretation of this Alzheimer's disease is still unclear".



Fig. 2. A neurofibrillary tangle, first described by Alois Alzheimer in Augusta D's brain (in Graeber, 2005). Figure by courtesy of the Prof. Manuel Graeber.

Prevalence of Neurodegenerative Diseases in the United States in 2000



Prusiner, S. B. N Engl J Med 2001;344:1516-1526

2019 ALZHEIMER'S DISEASE FACTS AND FIGURES

5.8 MILLION Americans are living with Alzheimer's

BY 2050, this number is projected to rise to nearly **14 MILLION**

MORE THAN 16 MILLION AMERICANS provide unpaid care for people with Alzheimer's or other dementias

These caregivers provided an estimated **18.5 BILLION HOURS** valued at nearly **$234 BILLION**

IN 2019, Alzheimer's and other dementias will cost the nation **$290 BILLION**

BY 2050, these costs could rise as high as **$1.1 TRILLION**

BUT ONLY **16%** say they receive regular cognitive assessments

EVERY 65 SECONDS someone in the United States develops the disease

Between 2000 and 2017 deaths from heart disease have decreased **9%**

while deaths from Alzheimer's disease have increased **145%**

1 IN 3 seniors dies with Alzheimer's or another dementia

It kills more than breast cancer and prostate cancer **COMBINED**

alzheimer's association


Alzheimer's and dementia patients worldwide
46.8m
World
9.4m
Americas
10.5m
Europe
4.0m
Africa
22.9m
Asia


People living with dementia around the world
29.9m 2050
15.8m 2030
9.4m 2015
Americas
15.8m 2050
7.0m 2030
4.0m 2015
Africa
18.6m 2050
13.4m 2030
10.5m 2015
Europe
67.2m 2050
38.5m 2030
22.9m 2015
Asia
131.5m 2050
74.7m 2030
46.8m 2015
World

Prevalence of AD in men and women



Nussbaum, R. L. et al. N Engl J Med 2003;348:1356-1364


Childhood risk factors for AD
Amyloidosis and adult
AD risk factors
Age-associated
brain pathologies
Prenatal
Genes
intellect and
learning disabilities
Early life
Education
body growth and development
ses and adversity
Adult brain at risk
Clinical phenotype

Genetic Factors Linked to Alzheimer's Disease

TABLE 2. GENETIC FACTORS LINKED TO ALZHEIMER'S DISEASE.*

GENETIC FACTOR	CHROMOSOME INVOLVED	AGE AT ONSET (YR)	PERCENTAGE OF EARLY-ONSET CASES LINKED TO FACTOR	PERCENTAGE OF ALL CASES LINKED TO FACTOR
Down's syndrome	21	>35	NA	NA
Amyloid precursor protein mutation	21	45–66	<1	<0.1
Presenilin 1 mutation	14	28–62	50	1–2
Presenilin 2 mutation	1	40–85	<1	<0.1
Alpha$_2$-macroglobulin mutation	12	>70	NA	30
Apolipoprotein E $\epsilon 4$ allele	19	>60	NA	40

*Modified from Marx.[21] NA denotes not applicable.

Martin, J. B. N Engl J Med 1999;340:1970-1980


ApoE Isoforms, Levels, and Lipidation
Aβ Aggregation
Synaptic plasticity and cognition
Neurotoxicity
Tau phosphorylation
Aβ Clearance
AD pathogenesis



Liu et al, Nat Rev Neurol. 2013; 9:106-118.


APP
PSEN1
PSEN2
Early Onset
AD Genes
Gene Function
APP Metabolism
Cholesterol Metabolism
Immune Response
Endocytosis
Cytoskeleton
Epigenetic
Pathology
Amyloid
Tau
Unknown
APOE4
+/+
APOE4
+/-
TREM2
ABCA7
CR1
ZCWPW1
CD33
PICALM
EPHA1
CLU
NME6
BIN1
INPP5D
100
50
10
5
1
0
10
20
30
40
50
ODDS RATIO (log scale)
POPULATION FREQUENCY (%)
Near
Certain
High
Risk
Medium
Risk
Low
Risk
RISK OF ALZHEIMER'S DISEASE

AD Key markers

Beta-Amyloid Plaques







Neurofibrillary Tangles






Amyloid Hypothesis
Neuronal Maintenance/Repair Hypothesis
Aβ Peptide
Age
Apolipoprotein E4
↑APP
↑Aβ Generation
tau
CNS Trauma
CNS Ischemia
Oxidative Stress
Cognitive Decline
Neurodegeneration

Critical areas affected by AD neuropathology



- **<u>Hyppocampus</u>**: target areas for memory encoding and retireval

-

- **<u>Lymbic system</u>**: emotional control together with parahippocampal structures and frontal areas

Normal BRAIN



Brain atrophy



Brain atrophy







Senile plaques and neurofibrillary tangles





Alzheimer´s disease related pathology - neurofibrillary pathology









Braak Staging System of NF pathology



Braak et al. 2006; from Kretzschmar HA, Nature Reviews 2009

Alzheimer´s disease related pathology - plaques





IHC Abeta



Bielschowsky



IHC hpTau/AT8

CERAD: The Consortium for Establishing a Registry for Alzheimer‘s Disease, 1991

amyloid/neuritic plaques





Definite AD: score C + dementia
Probable AD: score B + dementia
Possible AD: score A + dementia
score B or C without dementia
no histological evidence of AD: score A without dementia

Age	*No*	*few*	*moderate*	*frequent*
< 50	0	C	C	C
50-75	0	B	C	C
75	0	A	B	C

Alzheimer´s disease related pathology - Abeta deposits



A-beta phases



Block	Region	Phase of Aβ aggregation				
		1	2	3	4	5
Frontal cortex	Grey/white matter	**One or more regions with Aβ**	One or more regions with Aβ	+	+	+
Temporal cortex	Grey/white matter			+	+	+
Parietal cortex	Grey/white matter			+	+	+
Occipital cortex	Grey/white matter			+	+	+
Hippocampus	Adjacent temporal cx grey/white matter			+	+	+
	Molecular layer of the dentate gyrus	–	**One or more regions with Aβ**	+/–	+	+
	CA4	–		+/–	+/–	+
	CA1	–		+	+	+
	Remnants of entorhinal area	–		+	+	+
Gyrus cinguli	Grey/white matter	–		+	+	+
Basal forebrain	Hypothalamus	–	–	**One or more regions with Aβ**	+	+
	Amygdaloid nuclei	–	–		+	+
	Nucleus basalis of Meynert	–	–		+	+
Striatum	Putamen	–	–		+	+
	Caudate nucleus	–	–		+	+
	Insular cortex grey/white matter	–	+/–	+	+	+
Midbrain	Central grey	–	–	–	**One or more regions with Aβ**	One or more regions with Aβ
	Substantia nigra	–	–	–		
Cerebellum						**One or more regions with Aβ**

Thal et al, 2006
Modified by Alafuzoff et al


MAYO
CLINIC

Cerebral amyloid angiopathy



Concomitant Alzheimer-pathology in DLB: McKeith criteria 2005

		Alzheimer-type Pathology		
		NIA-Reagan Low (Braak stage O-II)	NIA-Reagan Intermediate (Braak stage III-IV)	NIA-Reagan High (Braak stage V-VI)
Lewy body type pathology	Brainstem predominant	Low	Low	Low
	Limbic (transitional)	High	Intermediate	Low
	Diffuse neocortical	High	High	Intermediate

Concomitant Lewy-body and Alzheimer-type pathology

Pattern of brain destruction in Parkinson's and Alzheimer's diseases

Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J.

J Neural Transm. 1996;103(4):455-90.

"…. In general, the extranigral destructions in PD are in themselves not sufficient to produce overt intellectual deterioration. Similarly, AD-related pathology up to stage III may be asymptomatic as well. Fully developed PD with concurring incipient AD, however, is likely to cause impaired cognition. Presently available data support the view that the occurrence of additional lesions in the form of AD stage III (or more) destruction is the most common cause of intellectual decline in PD."

Minimental state score and AD milestones




AD brain changes start decades before symptoms show
Amnestic MCI: memory problems; other cognitive functions OK; brain compensates for changes
Cognitive decline accelerates after AD diagnosis
Normal age-related memory loss
Total loss of independent function
Birth
40
60
80
Death
Life Course
Healthy Aging
Amnestic MCI
Clinically Diagnosed AD

doi:10.1093/brain/awh451 *Brain* (2005), **128**, 1093–1101

The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study

Hélène Amieva,[1] Hélène Jacqmin-Gadda,[2] Jean-Marc Orgogozo,[1,3] Nicolas Le Carret,[1] Catherine Helmer,[1] Luc Letenneur,[1] Pascale Barberger-Gateau,[1] Colette Fabrigoule[1] and Jean-François Dartigues[1,3]

Table 1 *Demographic and health characteristics of subjects at entry in the Paquid cohort*

	Non-Alzheimer's disease subjects (n = 1050) %	Alzheimer's disease subjects (n = 215) %
Age at diagnosis or 10 year follow-up		
<86	80.5 (n = 845)	50.2 (n = 108)
⩾86	19.5 (n = 205)	49.8 (n = 107)
Sex		
Men	39.3 (n = 413)	28.4 (n = 61)
Women	60.3 (n = 637)	71.6 (n = 154)
Educational level		
No diploma	22.7 (n = 238)	49.3 (n = 106)
Primary school with diploma or +	81.3 (n = 812)	50.7 (n = 109)
Rural place of residence	35.8	38.6



Fig. 1 Estimated evolution of the mean MMSE score (and 95% confidence bands) during the 9 years preceding the last visit (for non-Alzheimer's disease cases) or the diagnosis (for Alzheimer's disease subjects). (**A**) Whole sample: red curve, non-Alzheimer's disease cases; blue curve, Alzheimer's disease

Available online at www.sciencedirect.com

SciVerse ScienceDirect

Journal homepage: www.elsevier.com/locate/cortex

Special issue: Research report

A computational linguistic measure of clustering behavior on semantic verbal fluency task predicts risk of future dementia in the Nun Study

Serguei V.S. Pakhomov [a,*] *and Laura S. Hemmy* [b,c]

[a] *University of Minnesota Center for Clinical and Cognitive Neuropharmacology, United States*
[b] *Department of Psychiatry, University of Minnesota, MN, United States*
[c] *Geriatric Research Education and Clinical Center (GRECC), Minneapolis VA System, United States*

All data were obtained as part of a Human Studies IRB approved protocol for the University of Minnesota Nun Study. The Nun Study is a longitudinal study of aging in 678 U.S. School Sisters of Notre Dame aged 75+ years. The participants in the Nun Study underwent cognitive assessments at regular intervals (waves of approximately 18 months) for up to 20 years of follow-up. Participants in the current study were limited to those sisters with two or more evaluation time

	School sisters of Notre Dame (N = 239; all female)	
	Mean	SD
Age	80.73	3.98
Years of education	16.96	1.62
MMSE score	28.39	1.60
Delayed word recall score	7.06	1.39
SVF score	18.05	4.75
MCS	.66	.33
MChS	.67	.35


Memory Impairment (wave 5 censor)
Semantic Verbal Fluency (SVF)
Mean Cluster Size (MCS)
Mean Chain Size (MChS)
Memory Impairment (wave 13 censor)
Semantic Verbal Fluency (SVF)
Mean Cluster Size (MCS)
Mean Chain Size (MChS)
Dementia Diagnosis (wave 5 censor)
Semantic Verbal Fluency (SVF)
Mean Cluster Size (MCS)
Mean Chain Size (MChS)
Dementia Diagnosis (wave 13 censor)
Semantic Verbal Fluency (SVF)
Mean Cluster Size (MCS)
Mean Chain Size (MChS)
.4
.5
.6
.7
.8
.9
1
1
Relative Risk

Diagnosis of Alzheimer's Disease

Alzheimer's disease is usually diagnosed clinically from the patient history, collateral history from relatives, and clinical observations, based on the presence of characteristic neurological and neuropsychological features and the absence of alternative conditions.

Advanced medical imaging with computed tomography (CT) or magnetic resonance imaging (MRI), and with single photon emission computer tomography (SPECT) or positron emission tomography (PET) can be used to help exclude other cerebral pathology or subtypes of dementia.

The diagnosis can be confirmed with very high accuracy post-mortem when brain material is available and can be examined histologically.




Severely Reduced
Glucose Metabolism


MRI
Normal
AD
[18F]FDG
min
max
© Institut Douglas / douglas.qc.ca


Normal Memory (No APOE-4)
Normal Memory (APOE-4)
Dementia
MRI
Baseline PET
Follow-Up PET

VBM study : AD vs Controls

AD volume loss compared with the controls in the hippocampus, entorhinal cortex, parietal and lateral posterior superior temporal regions, and medial posterior portion of the cingulate gyrus.



Appel J et al.,Neuro 2009

Progressive atrophy detectable in AD

Preclinical AD





Entorinal Cortex

Hippocampus

Memory deficits

Language problems

Mild to Moderate AD





Progressice cortical atrophy

Increased Cognitive deficits

Mild behavioural problems

Severe AD



Overall brain atrophy

Loss of autonomy

Moderate behavioural and cognitive deficits

Loss of outside comunication

Mapping the evolution of regional atrophy in Alzheimer's disease

Preclinical AD

Mild AD

Moderate AD



Scahill *et al. 2008*

Progessive atrophy in presymptomatic Alzheimer's disease







C=very healthy elderly
B=normal ageing
A=AD

Fox et al., 2004

Hippocampal atrophy as a biomarker of AD





- Sensitivity and specificity > 80%

de Leon et al, 2004

Neuroimage. 2010 Jul 15;51(4):1345-59. Epub 2010 Mar 15.

Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease.

Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, Macdonald K, Schuff N, Fox NC, Ourselin S; Alzheimer's Disease Neuroimaging Initiative.

Healthy elderly



MCI



AD



Leung et al 2010

MCI subtypes – identifying aetiology with MRI

Neurodegenerative MCI



Vascular



Meyer et al, 2005

Amnestic MCI subtype

Deficits in cerebral blood flow in the hippocampus and other areas





From: **Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease**

JAMA Neurol. 2014;71(9):1111-1122. doi:10.1001/jamaneurol.2014.1654



Figure Legend:

Regions of InterestIndividual regions of interest are displayed on brain surfaces along with intranetwork connections in each of the 5 networks analyzed in the current study. CON indicates executive control network; DAN, dorsal attention network; DMN, default mode network; SAL, salience network; and SMN, sensorimotor network.

From: **Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease**



Similarities Within Resting State Network (RSN) Changes in Late-Onset Alzheimer Disease (LOAD) and Autosomal Dominant Alzheimer Disease (ADAD)Changes in intranetwork resting-state functional connectivity magnetic resonance imaging (rs-fcMRI) composite scores for participants with ADAD and participants with LOAD as a function of the Clinical Dementia Rating (CDR) Scale. For both ADAD and LOAD, a stepwise loss of functional connectivity was seen for most RSNs with an increasing CDR. Whiskers extend to 1.5 × interquartile range. M– indicates mutation negative and M+, mutation positive.[a]$P < .05$.[b]$P < .005$.[c]$P < .001$.

From: **Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease**

JAMA Neurol. 2014;71(9):1111-1122. doi:10.1001/jamaneurol.2014.1654



Figure Legend:

Similarities Between Resting State Network (RSN) Changes in Late-Onset Alzheimer Disease (LOAD) and Autosomal Dominant Alzheimer Disease (ADAD)Changes in internetwork composite scores for participants with ADAD and participants with LOAD as a function of Clinical Dementia Rating (CDR) status. A loss of between-network functional connectivity was seen for the default mode network–dorsal attention network and default mode network–sensorimotor network with an increasing CDR, although for executive control network–sensorimotor network, this pattern was only present in LOAD. Whiskers extend to 1.5 × interquartile range. M– indicates mutation negative and M+, mutation positive. $^{a}P < .05$ $^{b}P < .005$ $^{c}P < .001$.

From: **Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease**

JAMA Neurol. 2014;71(9):1111-1122. doi:10.1001/jamaneurol.2014.1654



Figure Legend:

Estimated Years from Symptom Onset Modulates Within Resting State Network Functional Connectivity in Autosomal Dominant Alzheimer DiseaseIntranetwork functional connectivity (and standard error bands) as a function of estimated years from symptom onset for all mutation positive (M+) and mutation negative (M–) individuals with autosomal dominant Alzheimer disease.

Amyloid β imaging

The most extensively studied and best validated tracer with positron emission tomography (PET) is the ^{11}carbon-labelled Pittsburgh Compound-B (^{11}C-PIB)

PIB binds specifically to fibrillar beta-amyloid (Aβ) deposits, and is a sensitive marker for Aβ pathology

Imaging β-amyloid burden in aging and dementia

NEUROLOGY 2007;68:1718-1725

Healthy controls:

- *21 no binding*
- *6 (22%) increased binding*
  - *pattern similar to AD*
  - *resembling the stages of Aβ deposition according to Braak pathological studies*





Prevalence of AD at age 85 from15 to 25%, but…
30% of non-demented >75 ys with moderate Aβ deposition at post-mortem

^{18}F-Flutemetamol Amyloid Imaging

AD case

Healthy elderly volunteer



Vandenberghe 2010

[C-11]PMP AChE PET images showing normal AChE biodistribution with most intense uptake in the basal ganglia, followed by the cerebellum, with lower levels in the cortex



Bohnen & Albin *Behav Brain Res* 2011


a
Memory deficit threshold
Disability threshold
Stage
Asymptomatic
MCI
Dementia
Memory tests
Language comprehension tests
Impairment (%)
1
2
3
4
5
–20 –15 –10 –5 0 5 10 Years from AD diagnosis
50 55 60 65 70 75 80 Age
b
Tau pathology
Stage
Asymptomatic
MCI
Dementia
Diagnosis
Impossible
With markers
Clinical (NINCDS–ADRDA criteria)
Amyloid markers
Functional/ metabolic markers
Entorhinal cortex atrophy
Hippocampal atrophy
Temporal neocortex
Whole-brain atrophy
Impairment (%)
–20 –15 –10 –5 0 5 10 Years from AD diagnosis

The Cholinergic System



Acetylcholine - ACh

- Most abundant NT in Peripheral N.S.
  - also found in Central N.S.
- Precursor = choline

  nutrient
- Degraded by acetylcholinesterase-
  - AChE

    Membrane bound - pre- & postsynaptic
- Nicotinic receptor - ionotropic
- Muscarinic receptor - metabotropic ~

Acetylcholine Synthesis



Ach - Distribution

- Peripheral N.S.
- Excites somatic muscle
- Autonomic NS
  - Ganglia
  - Parasympathetic NS
  - Neuroeffector junction
- Central N.S. - widespread
  - Hippocampus
  - Hypothalamus ~

Figure 1:

Natural History of Alzheimer's Disease and Stage-specific Symptomatic Drugs



Modified from Jelic & Winblad, 2004 (unpublished)

Implanted Deep Brain Stimulation system






A
Hippocampus
Entorhinal cortex
Fimbria
Fornix
Mammillary bodies
B

Brain Stimulation 8 (2015) 645–654

Contents lists available at ScienceDirect

Brain Stimulation

journal homepage: www.brainstimjrnl.com

Original Article

Deep Brain Stimulation Influences Brain Structure in Alzheimer's Disease

Tejas Sankar [a,1], M. Mallar Chakravarty [b,1], Agustin Bescos [c], Monica Lara [d], Toshiki Obuchi [e], Adrian W. Laxton [f], Mary Pat McAndrews [g], David F. Tang-Wai [h,i], Clifford I. Workman [j], Gwenn S. Smith [j], Andres M. Lozano [k,*]


A
Observer 1
Observer 2
Patient #
% Hippocampal Volume Change at one year
B
Patient #
Worse
Better
%change in ADAS-Cog score at one year
C
$r^2 = 0.45$
p = 0.15
% Hippocampal Volume Change
%change ADAS-Cog
D
$r^2 = 0.76$
p = 0.054
% Hippocampal Volume Change
%change ADAS-Cog

Hippocampal volume changes after one year of continuous fornix DBS and associated cognitive change



Comparison of baseline hippocampal volume and hippocampal atrophy rate between fornix DBS and matched AD patients



Brain-wide structural effects of fornix DBS in AD assessed using deformation-based morphometry (DBM). Axial brain slices showing representative clusters of volume increase across all patients following one year of fornix DBS.